This study was undertaken to determine whether patients with chronic use of H2-receptor antagonists (HRA) had demonstrable decreases in bone mineral density ( ...

6 мар. 2012 г. · Some medications prescribed for common health problems, such as heartburn or depression, could affect your bone health.

It has been reported that ASDs may interfere with bone metabolism and thus increase fracture risk. Some potential mechanisms by which PPI therapy may lead to ...

Multiple studies indicated the use of PPIs or H2RAs is associated with higher risk of fracture or bone loss (6–9). However, result from a PPI user cohort ...

15 сент. 2015 г. · Long-term use of PPIs can increase the risk for fractures, especially hip fractures. The FDA has revised the prescription and OTC labels for this drug class.

These bone changes were more prominent in old age. Also, Famotidine administration produced bone changes only in old age.

This study was undertaken to determine whether patients with chronic use of H2-receptor antagonists (HRA) had demonstrable decreases in bone mineral density. ( ...

4 апр. 2023 г. · Although no interaction between bisphosphonates and PPIs is documented, the increased risk of fractures when given together should be reviewed and managed.

Ranitidine proved safer than pantoprazole for patients with high risk of osteoporosis and in alendronate-treated patients.

Each medication has its own risks, however, omeprazole can cause more long-term adverse effects in comparison to famotidine. These include osteoporosis, low ...